Novo Nordisk's Wegovy supply chain challenges should be resolved by year end

4 March 2022

Danish diabetes care giant Novo Nordisk’s (NOV: N) success in diabetes and obesity drug sales could be impacted by supply chain issues, for the production of its obesity drug Wegovy (semaglutide), unless it can resolve issues with its contract manufacturer.

Wegovy became the first once-weekly GLP-1 therapy to be approved for weight management in the USA in June last year, in the UK in September and was recommended for approval in Europe in November.

Data and analytics company GlobalData expects Novo Nordisk to successfully overcome the supply challenges surrounding Wegovy in the second half of 2022 and that the drug will likely become a blockbuster therapy for obesity from 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK